ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial

Daiichi Sankyo and AstraZeneca’s ENHERTU also demonstrated a clinically meaningful progression-free survival improvement in patients with HER2 ultralow expression



Plans for global regulatory...

Related Keywords

Jerusalem ,Israel General ,Israel ,Daiichi Sankyo ,National Cancer Institute ,Daiichi Sankyo Inc ,Low Metastatic Breast Cancer ,Solid Tumors ,Positive Locally Advanced ,Metastatic Gastric Cancer ,Adverse Reactions ,Positive Metastatic Breast Cancer ,Mutant Unresectable ,Metastatic Solid Tumors ,Reproductive Potential ,Hepatic Impairment ,Prescribing Information ,Cancer Res ,Stat Facts ,Female Breast Cancer ,Accessed April ,Pathol Transl ,Markets ,